drug
tecovirimat
Marketedupdated 5mo agoby $NNVC NANOVIRICIDES, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying tecovirimat
- phase4Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG
- —A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox
- phase2Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
- phase3Study of Tecovirimat for Human Mpox Virus
- —Tecovirimat Intravenous Treatment for Orthopox Virus Exposure
- phase4Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
- phase3Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 23, 2027
291 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Aug 8, 2032method-of-use (U-2346)US 11890270
- Sep 4, 2031method-of-use (U-2346)US 77371684.9y
- Sep 4, 2031method-of-use (U-3377)US 77371684.9y
- Aug 2, 2031formulationUS 105761654.8y
- Aug 2, 2031formulationUS 92330974.8y
- Aug 2, 2031method-of-use (U-3377)US 99078594.8y
- Mar 23, 2031formulationUS 124338684.5y
- Mar 23, 2031compositionUS 93394664.5y
- Jul 23, 2027formulationUS 8039504291d
- Jul 23, 2027formulationUS 8039504291d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that